预约演示
更新于：2026-04-02
Iberdomide
伊伯多胺
更新于：2026-04-02
概要
基本信息
药物类型 降解型分子胶 |
别名 IBER、Iberdomide (USAN/INN)、Iberdomide hydrochloride + [4] |
作用方式 降解剂 |
作用机制 IKZF1 降解剂(DNA结合蛋白IKAROS 降解剂)、IKZF3 降解剂(锌指蛋白Aiolos 降解剂) |
非在研适应症 |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H27N3O5 |
InChIKeyIXZOHGPZAQLIBH-NRFANRHFSA-N |
CAS号1323403-33-3 |
关联
53
项与 伊伯多胺 相关的临床试验NCT07437963
Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
NCT06896916
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
NCT06348108
A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
100 项与 伊伯多胺 相关的临床结果
登录后查看更多信息
100 项与 伊伯多胺 相关的转化医学
登录后查看更多信息
100 项与 伊伯多胺 相关的专利（医药）
登录后查看更多信息
79
项与 伊伯多胺 相关的文献（医药）2026-01-01Lancet Haematology
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial
Article
作者: Roeloffzen, Wilfried W H ; Verkleij, Christie P M ; de Ruijter, Maaike E M ; Wegman, Jurgen ; Zweegman, Sonja ; Nijhof, Inger S ; Smits, Febe ; de Weerdt, Okke ; Nasserinejad, Kazem ; Kerstiens, Ramses ; Smit, Nina ; Franssen, Laurens E ; Mutis, Tuna ; de Kort, Elizabeth A ; Korst, Charlotte L B M ; Croockewit, Alexandra J ; van de Donk, Niels W C J ; Levin, Mark-David ; Plattel, Wouter ; van der Spek, Ellen ; van der Klift, Marjolein ; Groen, Kaz ; Westerman, Matthijs
BACKGROUND:
Iberdomide is an oral cereblon E3 ligase modulator with higher affinity to cereblon than immunomodulatory drugs, leading to improved direct anti-myeloma activity and enhanced immunostimulatory effects. We aimed to evaluate the safety and activity of iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd) in patients with relapsed and refractory multiple myeloma.
METHODS:
The ICON study is a prospective, single-arm, phase 2, open-label study conducted in eight hospitals in the Netherlands. We enrolled patients (aged ≥18 years) with relapsed and refractory multiple myeloma (lenalidomide-refractory) who had received two to four previous lines of therapy and had a WHO performance status of 0-2. Patients were treated with oral iberdomide (1·6 mg/day on days 1-21 of each 28-day cycle), oral low-dose cyclophosphamide (50 mg/day on days 1-28), and oral dexamethasone (40 mg [20 mg in patients age >75 years] once a week) until progression. All patients received thrombosis prophylaxis daily: 80 mg oral aspirin or 100 mg oral carbasalate calcium. Patients with a previous history of venous thromboembolism received only low molecular-weight heparin by subcutaneous injection. The primary endpoint was progression-free survival, defined as time from the start of treatment to the date of progression or death. Activity and safety were assessed in all patients who started treatment. This trial was registered at ClinicalTrials.gov (NCT04392037) and is ongoing.
FINDINGS:
Between Feb 17, 2021, and July 7, 2023, 61 patients were enrolled and received IberCd treatment (29 [48%] were female and 32 [52%] patients were male). The median number of previous lines of therapy was 3 (range 2-5); 52 (85%) patients were triple-class exposed and 27 (44%) had triple-class refractory disease. 50 patients discontinued study treatment, 39 of whom due to progressive disease, but all 61 patients were included in the main analysis population. After a median follow-up of 25·4 months (IQR 19·7-31·6), the median progression-free survival was 17·6 months (one-sided 95% CI 16·6-19·9). In all 61 patients, the most common grade 3-4 adverse events were neutropenia (34 [56%] patients) and infections (21 [34%] patients). Treatment-related serious adverse events were reported in 25 (41%) patients, with infections being the most common (34 [71%] of 48 serious adverse events). Treatment-related death occurred in one (2%) patient due to COVID-19.
INTERPRETATION:
IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments.
FUNDING:
Bristol Myers Squibb.
2025-08-01JOURNAL OF MEDICAL VIROLOGY
Novel Cereblon‐Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus‐ Associated Lymphomas In Vitro
Article
作者: Davis, David A. ; Shrestha, Prabha ; Treco, Emma N. ; Yarchoan, Robert
ABSTRACT:
Primary effusion lymphoma (PEL), which is caused by Kaposi sarcoma herpesvirus (KSHV), and Burkitt lymphoma (BL), a subset of which are associated with Epstein‐Barr virus (EBV), are aggressive non‐Hodgkin's lymphomas. Both have relatively poor survival compared to other lymphomas. Cereblon‐binding immunomodulators (CBIs), such as pomalidomide (Pom), show in vitro efficacy and clinical activity against certain of these lymphomas. Next generation CBIs, such as golcadomide (Golc) and iberdomide (Iber), have increased affinity to the primary cellular target, cereblon, making them potentially better anticancer agents. Here, we report the in vitro activity of these novel CBIs against PEL and BL cell lines. Both Golc and Iber, but primarily Golc, caused substantial growth suppression of PEL and BL lines with much lower half‐maximal inhibitory concentration (IC50) compared to Pom. This growth suppression was mediated, in part, by enhanced downregulation of interferon regulatory factor 4 (IRF4) in PEL cell lines. Additionally, both Golc and Iber increased immune surface markers such as ICAM‐1, B7‐2, and MHC‐I in PEL and BL cells at lower concentrations than Pom; these increases led to enhanced recognition of both PEL and BL cells by T‐cells. The novel CBIs had relatively little activity in Pom‐resistant cell lines with low levels of cereblon, suggesting that binding to cereblon is also important for the functions of the novel CBIs. These data show that the newer CBIs are more potent and effective against PEL and BL lines than Pom, and therefore, are worth investigating clinically in patients with these tumors.
2025-08-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Comparative effects of biologics and small molecule inhibitors on cutaneous disease activity in lupus erythematosus: A systematic review and network meta-analysis
Article
作者: Gou, David ; Sun, Wayne ; Rayner, Daniel G ; Xi, Cheng En ; Silang, Isabella ; Dutz, Jan P ; Khosravi-Hafshejani, Touraj
Meta-anal. of comparative effects of biologics and small mol. inhibitors on cutaneous disease activity in lupus erythematosus.Our review builds upon the limitations of previous network meta-analyses by including 29 more trials investigating 25 addnl. unique interventions in our analyses on CLASI-A scores.In addition to anifrolumab, deucravacitinib, and litifilimab, we identified superior efficacy of sifalimumab and daxdilimab compared to placebo-all of which target the type 1 interferon pathway. Litifilimab and daxdilimab inhibit BDCA2 and Ig-like transcript 7, resp., which reside on dendritic cells and stimulate the production of type 1 interferons.Meanwhile, sifalimumab directly inhibits interferon-, and anifrolumab and deucravacitinib target the interferon-receptor and tyrosine kinase 2, resp.-two proteins involved in the interferon signaling pathway.These findings support the continued investigation of the type 1 interferon pathway in the management of CLE.
100 项与 伊伯多胺 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性多发性骨髓瘤 | 申请上市 | 美国 | 2026-02-17 | |
| 复发性多发性骨髓瘤 | 申请上市 | 美国 | 2026-02-17 | |
| 多发性骨髓瘤 | 申请上市 | 中国 | 2025-12-29 | |
| 多发性骨髓瘤 | 申请上市 | 中国 | 2025-12-29 | |
| 阴燃多发性骨髓瘤 | 临床2期 | 美国 | 2021-11-02 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 美国 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 奥地利 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 比利时 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 法国 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 韩国 | 2021-10-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 多发性骨髓瘤 维持 | 15 | 簾獵選遞廠範鏇鬱鑰願(鹹膚壓鏇積窪遞觸製艱) = neutropenia (n=1), rash (n=2), and infections (n=3). 壓顧衊壓鏇蓋範蓋築鬱 (觸鹹糧壓築窪構網繭顧 ) 更多 | 积极 | 2026-02-04 | ||
临床2期 | 61 | (relapsed and refractory multiple myeloma) | 蓋繭繭願願簾獵淵淵選(艱選簾觸蓋鹽膚壓築範) = 34% of patients experienced infections 壓築齋廠餘糧憲餘獵築 (艱築鹹繭積醖簾願構蓋 ) 更多 | 积极 | 2026-01-01 | ||
临床1期 | 29 | 鏇鬱積鏇鏇衊顧衊糧遞(觸製艱餘艱窪網壓夢網) = 齋積廠選顧築遞艱壓齋 鬱憲鹹觸積窪蓋獵鑰蓋 (製遞鬱壓簾製簾廠醖糧, 50.3 ~ 82.6) 更多 | 积极 | 2025-12-06 | |||
临床2期 | 维持 | 15 | 選觸襯壓構衊糧餘觸繭(構鬱壓艱鏇衊憲鬱淵繭) = 鏇艱積窪鹹獵憲觸窪網 憲築憲衊醖獵醖繭遞壓 (廠觸遞膚窪遞醖繭顧壓 ) 更多 | 积极 | 2025-12-06 | ||
临床2期 | 多发性骨髓瘤 维持 | 120 | 構齋淵艱艱窪廠艱網艱(製糧鹹選選醖鹽構構壓) = neutropenia (48% in the 0.75 mg, 58% in the 1.0 mg, and 60% in the 1.3 mg cohorts), followed by infections (8%, 18%, and 18%; mostly respiratory infections). Grade ≥3 rash was more frequent in the 1.3 mg cohort (10%), compared to 0.75 mg (0%) and 1.0 mg (3%) cohorts. There were no grade ≥3 AEs of thrombocytopenia, anemia, or venous thromboembolism. Only 1 of 120 pts (0.8%) developed grade ≥3 neuropathy (1.3 mg), and 1 (0.8%) developed grade 3 diarrhea (1.0 mg). 蓋衊艱簾願築積淵膚淵 (觸蓋餘鑰鬱遞襯觸蓋廠 ) | 积极 | 2025-12-06 | ||
临床2期 | 30 | 願網選衊範選襯獵顧壓(艱鬱願膚襯鹹壓鑰鏇鏇) = Grade 3 or greater events included neutropenia (50%), lymphocytopenia (40%), leukopenia (23%), thrombocytopenia (10%), and anemia (3%) but were manageable with growth factor support and/or iber dose-reduction, as needed. 遞窪膚鬱糧鹽選網鏇鹽 (鑰鑰範壓鏇艱窪蓋顧壓 ) 更多 | 积极 | 2025-12-06 | |||
临床1/2期 | 多发性骨髓瘤 t(11;14) | 20 | 獵壓網醖鹹範鬱餘衊製(觸遞憲餘觸襯淵醖範窪) = 廠襯鏇顧鏇願鬱淵鹹蓋 齋築顧窪夢鹽鹹選膚網 (齋築醖鹹窪觸衊選齋齋 ) 更多 | 积极 | 2025-12-06 | ||
临床1/2期 | 75 | 遞簾選鏇繭窪網願觸積(蓋窪窪鏇壓獵齋鹽獵網) = 製衊構簾簾範繭範顧憲 糧願鏇鏇鏇鏇艱獵衊淵 (窪齋憲夢鹹簾繭憲糧選 ) 更多 | 积极 | 2025-12-06 | |||
(No renal impairment) | 遞簾選鏇繭窪網願觸積(蓋窪窪鏇壓獵齋鹽獵網) = 夢積鹹鏇襯簾鹹膚製選 糧願鏇鏇鏇鏇艱獵衊淵 (窪齋憲夢鹹簾繭憲糧選 ) 更多 | ||||||
临床3期 | 664 | 艱顧壓鑰糧蓋遞淵構夢(窪範壓憲製憲艱餘構艱) = demonstrated a statistically significant improvement 齋衊選齋廠簾窪顧廠選 (鑰窪齋膚積鏇窪繭構鏇 ) | 积极 | 2025-09-23 | |||
临床1/2期 | 18 | 憲範齋積構憲淵淵鏇衊(膚糧廠簾憲構餘積窪衊) = 14 (82.4%) pts had grade (Gr) 3/4 treatment-emergent AEs (TEAEs); primarily infections (47.1%), including pneumonia (17.6%) and COVID-19 (11.8%) 鑰網構築鹹廠範顧鏇醖 (製鹽壓餘遞夢築窪範獵 ) 更多 | 积极 | 2025-05-30 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用